OR WAIT 15 SECS
Henry Schein has entered into an exclusive agreement with Radic8 to distribute their devices to the US and Canada.
Henry Schein has entered into an exclusive agreement with Radic8, a UK-based manufacturer of air purifier systems, to distribute their devices to the US and Canada*, the company announced in a press release.
The Radic8 VirusKiller™ is currently being marketed under the US Food and Drug Administration enforcement policy for air purifiers during COVID-19 pandemic The product is intended to be effective against SARS-CoV-2 based on its demonstrated effectiveness against similar viruses that are just as hard or harder to kill.** The results are said to show a 99.9999%, 6 log reaction, kill rate in a single air pass. The kill rate is used to describe what percentage of a given germ is killed by a particular process or disinfectant, the statement read.
“We’re pleased to announce this exclusive agreement with Radic8, as we know that patient safety is a top priority for dental professionals, and air purification systems can help practices improve indoor infection control, reducing the risk of exposure to certain pathogens,” said AJ Caffentzis, president, US. dental distribution. “We’re excited to add Radic8 air purification devices to our portfolio of air management technologies, reinforcing Henry Schein’s commitment to helping dental professionals provide a safer environment for their patients and staff.”
Three different models of the Radic8 air purifier are available through Henry Schein:
For more information, visit henryscheindigital.com/radic8.
*The Radic8 air purifier is not FDA-cleared or FDA-approved.
**The Radic8 air purifier has not been tested against SARS-CoV-2 but has been tested against harder to kill viruses, such as the adenovirus.